A Critical Juncture for UK Healthcare: Balancing Innovation and Sustainability
In a recent development, pharmacy leaders have voiced their concerns about the potential impact of NICE's threshold increase on the generics market. This issue, which could have far-reaching consequences for the UK's healthcare system, has sparked a debate among stakeholders.
Pharmacy leaders, including the Company Chemists' Association and Community Pharmacy England, have penned a letter to Baroness Morris, chairing the House of Lords Public Services Committee. Dated December 5, 2025, the letter calls for a review of drug pricing and margin structures to address the growing number of medicines supplied to the NHS at a loss.
The crux of the matter lies in the recent UK-US agreement, which commits to increasing prices for new branded medicines. Pharmacy stakeholders argue that this increase should not be funded by further squeezing the generics market, which already accounts for a staggering four out of five NHS primary care prescriptions.
The Generics Conundrum: A Tale of Savings and Shortages
Community pharmacies have long been the driving force behind competitive procurement of medicines for the NHS, resulting in significantly reduced prices for generic medicines. This model has been a boon for taxpayers, saving billions of pounds. However, the letter highlights a concerning trend: the reimbursement price for over 850 million generic medicine packs is now 99p or less, a situation deemed unsustainable.
The impact of these low prices is evident. Several global manufacturers have shifted their focus to other markets or withdrawn entirely from the UK, leading to medicine shortages in some cases. These shortages are entirely avoidable, yet they underscore the fragile state of the generics market.
A Call for Review and Reform
The stakeholders' letter proposes a two-pronged approach. Firstly, they advocate for a review of drug tariff pricing and retained margins to reduce the number of medicines supplied to the NHS at a loss. Secondly, they call for the creation of a procurement model that ensures financial sustainability for all parts of the domestic supply chain.
On December 1, 2025, NICE announced an increase in cost-effectiveness thresholds, allowing the NHS in England to spend up to 25% more on new medicines. The new thresholds permit spending of £25,000 to £35,000 per quality-adjusted life year gained by a new drug, compared to the previous range of £20,000 to £30,000.
The House of Lords Public Services Committee is currently investigating medicine shortages and supply issues. In an evidence session held in October 2025, Keith Ridge, the former chief pharmaceutical officer for England, expressed concerns about the lack of explicit government policy on stockpiling critical medicines.
A Thought-Provoking Conclusion: Your Turn!
This issue raises important questions: How can we balance the need for innovative, branded medicines with the sustainability of the generics market? Should the generics market bear the brunt of funding increases for new branded medicines? And what role should government policy play in ensuring a stable supply of critical medicines?
Share your thoughts in the comments! We'd love to hear your perspective on this complex healthcare debate.
